## **Core Concept**
Acute Myeloid Leukemia (AML) is a heterogeneous group of diseases characterized by the clonal expansion of myeloid blasts in the bone marrow and peripheral blood. The prognosis in AML is influenced by various factors, including cytogenetic abnormalities, molecular genetic mutations, and clinical features. Understanding these factors is crucial for determining the prognosis and guiding treatment decisions.

## **Why the Correct Answer is Right**
The correct answer, , is associated with a poorer prognosis in AML. This is because certain cytogenetic and molecular abnormalities are linked to a higher risk of treatment failure and shorter overall survival. For instance, complex karyotype, abnormalities in chromosomes 5 and 7, and specific molecular mutations such as FLT3-ITD without NPM1 mutation are generally considered adverse prognostic indicators.

## **Why Each Wrong Option is Incorrect**
- **Option A:** is generally considered a favorable prognostic indicator in AML. Patients with this abnormality tend to have a better response to treatment and longer survival rates.
- **Option B:** is associated with a favorable prognosis, particularly when it occurs in the context of certain molecular mutations.
- **Option C:** is also a marker of a relatively favorable prognosis in AML, especially when treated with targeted therapies.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl in AML is the importance of molecular and cytogenetic characterization for risk stratification. For example, the presence of NPM1 mutation without FLT3-ITD is associated with a more favorable prognosis, whereas FLT3-ITD positivity, especially in the absence of NPM1 mutation, confers a worse prognosis. This information is critical for guiding treatment decisions, including the potential use of allogeneic stem cell transplantation.

## **Correct Answer:** .